May. 13 at 10:41 AM
Citizens on
$KURA said, We reiterate our Market Outperform rating and price target of
$24 for Kura Oncology based on a discounted EPS and revenue multiple analysis.
$SNDX ABBV BMY RHHBY DSNKY PFE
$RIGL
Citizens added—Yesterday, Kura announced 1Q26 financial results, provided updates on the KOMZIFTI (ziftomenib, zifto) launch and discussed milestones for 2026.
Of note, the registrational Phase 3 KOMET-017 trial is enrolling ahead of expectations, with the potential for top-line results for the intensive chemo combo as early as 2028.
With signs pointing to a strong KOMZIFTI launch, the frontline AML trials fully funded, the FTI program progressing in the clinic, and a cash position of
$580.8MM,
we believe Kura shares represent an attractive investment opportunity, with ~59% downside (bear case of
$4) and ~200% upside (bull case of
$29).
